During the Energy and Commerce Committee markup of Speaker Pelosi’s prescription Drug Plan (H.R. 3), Congressman raised serious concerns that the bill would have a chilling effect on vital life-saving medical innovation, driving both investment and jobs overseas to places like China, while potentially compromising the oversight and safety of prescription drugs.

0 Comments